Concepedia

Author

Egon Pfarr

Boehringer Ingelheim (Germany)

Also Known As

E PFARR, E Pfarr, E. Pfarr, EGON PFARR, Egon Pfarr

35

Publications

2.5K

Citations

14

H-Index

17

Concepts

All Affiliations

Boehringer Ingelheim (Germany)The University of Texas Southwestern Medical CenterDallas Diabetes Research CenterMonash UniversityBoehringer Ingelheim (Norway)
EP

About

Egon Pfarr is an author at Boehringer Ingelheim (Germany) specializing in medicine, cardiovascular disease, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

335

2

Diabetes

2

2

193

3

Health Sciences

1

1

171

4

Public Health

1

1

22

5

Health Policy

1

1

22

Egon Pfarr

×

14

Publications

2.5K

Citations

14

H-Index

YearCitations

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen,

JAMA

2018

1K

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen,

JAMA

2019

578

Darusentan: An effective endothelinA receptor antagonist for treatment of hypertension

Roumen Nakov, Egon Pfarr, Siegfried Eberle,

American Journal of Hypertension

2002

172

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

David Z.I. Cherney, Søren S. Lund, Bruce A. Perkins,

Diabetologia

2016

171

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Darren K. McGuire, John H. Alexander, Odd Erik Johansen,

Circulation

2019

157

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Julio Rosenstock, Vlado Perkovic, John H. Alexander,

Cardiovascular Diabetology

2018

82

Efficacy and Tolerability of Alitretinoin for Chronic Hand Eczema Under Daily Practice Conditions: Results of the TOCCATA Open Study Comprising 680 Patients

T. L. Diepgen, Egon Pfarr, T Zimmermann

Acta Dermato Venereologica

2012

73

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Vlado Perkovic, Robert D. Toto, Mark E. Cooper,

Diabetes Care

2020

58

Carvedilol versus verapamil in chronic stable angina: a multicentre trial

U. Hauf-Zachariou, Roger Blackwood, Kulasiri A. Gunawardena,

European Journal of Clinical Pharmacology

1997

40

Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris

R. van der Does, U. Hauf-Zachariou, Egon Pfarr,

The American Journal of Cardiology

1999

29

Page 1